同期整合加量调强放疗在食管癌中的应用进展  

Research progress on application of simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma

作　　者：王澜[1] 王亚敏 刘丽虹[1] 刘树堂[1] 韩春[1] 于金明 Wang Lan;Wang Yamin;Liu Lihong;Liu Shutang;Han Chun;Yu Jinming(Department of Radiation Oncology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Shandong,Ji'nan 250017,China)

机构地区：[1]河北医科大学第四医院放疗科,石家庄050011 [2]山东省肿瘤防治研究院(山东省肿瘤医院)山东第一医科大学(山东省医学科学院)放疗科,济南250117

出　　处：《中华放射肿瘤学杂志》2021年第11期1216-1220,共5页Chinese Journal of Radiation Oncology

基　　金：国家重点研发计划项目(2018YFC1313203);国家卫生计生委医院管理研究所项目(WJWYGS-201816)。

摘　　要：近年非常规分割放疗在多个系统肿瘤的治疗中日益体现出优势。同期整合加量调强放疗(SIB-IMRT)可以在一次照射过程中将不同的分割剂量传递至不同区域,实现在不增加正常组织受量前提下给予高危区域(GTV)局部追加剂量照射,其剂量学优势已得到学界广泛认可。目前,在食管癌领域SIB-IMRT的局控、生存优势、适应证人群、单次分割整合加量的上限界点仍然不明确,特就该技术在食管癌中的应用予以综述。In recent years,unconventional fractionated radiotherapy has shown increasing advantages in the treatment of multiple system tumors.Simultaneous integrated boost intensity-modulated radiotherapy(SIB-IMRT)involves the delivery of standard-fraction doses of radiotherapy to different areas,achieving the delivery of higher doses of radiotherapy per fraction to the high-risk gross tumor volume(GTV)without sacrificing the irradiation dose to the normal tissues.The dosimetric advantages of SIB-IMRT have been widely recognized.At present,the local control,survival advantage,indication population and the optimal upper limit of single fraction of SIB-IMRT for esophageal carcinoma are still unclear.This article reviews the application of SIB-IMRT in esophageal carcinoma.

关 键 词：食管肿瘤/调强放射疗法 同期整合加量 应用进展 

分 类 号：R735.1[医药卫生—肿瘤]